CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 88 target
Drug / intervention
577-MPL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02735213
NCT02735213Phase 3Completed
CompareCT.gov

A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy

The Eye Hospital of Wenzhou Medical University·interventional·Posted Apr 12, 2016·Updated Jul 18, 2019

In Brief

A Phase 3 clinical trial evaluating 577-MPL and TLT for Central Serous Choroidopathy. Completed, enrolled 88 participants across 1 site.

Detailed Summary

The purpose of this study is to observe whether micropulse laser (MPL) is noninferiority to traditional laser therapy in central serous chorioretinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCentral Serous Choroidopathy
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 12, 2016
Enrollment StartMar 1, 2016
Primary CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.2 years ago

Interventions

577-MPLdevice

9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250\~400 milliWatts of power(50% threshold power),150\~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.

TLTdevice

contimuous wave,100um spot size, 0.05 seconds duration, 55\~60 milliwatts of power, 18\~27 spots,the laser area is the corresponding leakage on mid-phase FA.